Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Prostate Cancer, Castration Resistant”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT03490838
What this trial is testing

177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer

Who this might be right for
Prostatic Neoplasm
Advanced Accelerator Applications 27
Early research (Phase 1)Active Not RecruitingNCT06303713
What this trial is testing

LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

Who this might be right for
Prostate CancerMetastatic Prostate CancerMetastatic Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute 37
Early research (Phase 1)Study completedNCT02363855
What this trial is testing

Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) Subjects

Who this might be right for
Prostatic Neoplasms
Bayer 9
Large-scale testing (Phase 3)Study completedNCT03834506
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

Who this might be right for
Prostatic Neoplasms
Merck Sharp & Dohme LLC 1,030
Early research (Phase 1)Study completedNCT03835533
What this trial is testing

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Parker Institute for Cancer Immunotherapy 43
Early research (Phase 1)Ended earlyNCT04677855
What this trial is testing

Study of PCUR-101 in Combination With ADT in Patients With mCRPC

Who this might be right for
Prostate Cancer
Pellficure Pharmaceuticals, Inc 7
Large-scale testing (Phase 3)Study completedNCT03511664
What this trial is testing

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Endocyte 861
Testing effectiveness (Phase 2)Ended earlyNCT03770455
What this trial is testing

Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Jodi Layton, MD 8
Early research (Phase 1)Study completedNCT00510718
What this trial is testing

MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer

Who this might be right for
Prostate CancerHormone Refractory Prostate Cancer
Pfizer 140
Testing effectiveness (Phase 2)WithdrawnNCT01368003
What this trial is testing

STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling

Who this might be right for
Adenocarcinoma of the Prostate
Toni Choueiri, MD
Early research (Phase 1)Looking for participantsNCT06705686
What this trial is testing

Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (CRPC)Metastatic Castration-resistant Prostate Carcinoma
TechnoGenesys, Inc. 40
Testing effectiveness (Phase 2)Looking for participantsNCT07549256
What this trial is testing

Cannabidiol for Pain Relief of Patients With End-stage mCRPC

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Regionshospital Nordjylland 58
Testing effectiveness (Phase 2)Looking for participantsNCT04704505
What this trial is testing

Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate AdenocarcinomaMetastatic Prostate AdenocarcinomaCastration-resistant
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 47
Testing effectiveness (Phase 2)Active Not RecruitingNCT05547061
What this trial is testing

A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy

Who this might be right for
Prostate CancermCRPC
Cellbion Co., Ltd. 91
Large-scale testing (Phase 3)WithdrawnNCT03800784
What this trial is testing

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

Who this might be right for
Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Testing effectiveness (Phase 2)Active Not RecruitingNCT04655365
What this trial is testing

Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.

Who this might be right for
Prostate Cancer
CHU de Quebec-Universite Laval 50
Testing effectiveness (Phase 2)Study completedNCT02453009
What this trial is testing

Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Santa Chiara Hospital 246
Large-scale testing (Phase 3)Study completedNCT04676334
What this trial is testing

CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib

Who this might be right for
Metastatic Castration-Resistant Prostate CancerOvarian CancerEpithelial Ovarian Cancer+3 more
pharmaand GmbH 34
Not applicableActive Not RecruitingNCT04141709
What this trial is testing

Local Ablative Radiotherapy for OLIgoprogressive Castration Resistant Prostate Cancer

Who this might be right for
Oligometastatic DiseaseProstatic Cancer, Castration-Resistant
Technische Universität Dresden 66
Testing effectiveness (Phase 2)Active Not RecruitingNCT03217747
What this trial is testing

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Who this might be right for
Advanced Malignant Solid NeoplasmCastration-Resistant Prostate CarcinomaMalignant Solid Neoplasm+7 more
M.D. Anderson Cancer Center 173
Next Page